SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
-----------------------------
FORM 8-K/A
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 10, 2003
ORPHAN MEDICAL, INC.
--------------------
(Exact name of registrant as specified in its charter)
Delaware 0-24760 41-1784594
-------- ------- ----------
(State or other jurisdiction (Commission file number) (I.R.S. employer
of incorporation) number) identification
Suite 250,
13911 Ridgedale Drive,
Minnetonka, MN 55305 (952) 513-6900
-------------- ----- --------------
(Address of principal (zip code) (Registrant's telephone number,
executive offices) including area code)
Not Applicable
--------------------------------------------------------------------------------
(Former name or former address, if changed since last report)
Item 7. Financial Statements and Exhibits
---------------------------------
(b) Pro Forma Financial Information
The Company previously reported the sale of Busulfex(R) (busulfan) Injection
on June 10, 2003. Pro forma financial statements are attached as Exhibit 99.2
to this Form 8-K/A.
The unaudited pro forma information presented in Exhibit 99.2 presents the
Company's statement of operations for the year ended December 31, 2002 and the
quarter ended March 31, 2003, assuming the sale of Busulfex(R) (busulfan)
Injection reported in Form 8-K dated June 12, 2003 took place effective as of
the beginning of each respective fiscal period presented. An unaudited pro forma
balance sheet as of March 31, 2003 is also presented and reflects the sale as of
March 31, 2003. The unaudited pro forma information presented is for
informational purposes only and is not necessarily indicative of the results of
operations had the sale of the product as of the dates indicated.
Exhibit List
------------
Exhibit 99.2 - Pro forma Financial Statements.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this Report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: June 25, 2003 ORPHAN MEDICAL, INC.
/s/ Timothy G. McGrath
----------------------
Timothy G. McGrath
Chief Financial Officer
(duly authorized officer and
principal financial officer)
EXHIBIT INDEX
Exhibit
Number Description
99.2 Pro forma Financial Statements